Why the study?
GDF-15 is an established cardiovascular risk marker implicated in tumour biology, but its relation to other cardiac biomarkers and prognostic value in treatment-naive cancer patients required exploration.
Does elevated plasma GDF-15 predict all-cause mortality in treatment-naïve cancer patients?
Does elevated plasma GDF-15 predict all-cause mortality in treatment-naïve cancer patients?
Elevated plasma GDF-15 is associated with disease severity, systemic inflammation, subclinical organ impairment, and poor prognosis in treatment-naïve patients with solid tumors, highlighting its potential role in cardio-oncology.
Answers are grounded in this paper and cite their sources.
May flag subclinical cardiac-inflammatory burden at cancer diagnosis but should not change practice; leaves open incremental utility and hematologic exceptions.
AIM: GDF-15 is an established cardiovascular risk marker but is equally implicated in tumour biology. Elevated levels of GDF-15 have indeed been observed in distinct tumour entities. This study aimed to explore the relation of GDF-15 to other cardiac biomarkers and the general association of GDF-15 on prognosis in an unselected cohort of treatment-naïve cancer patients. METHODS: We prospectively enrolled 555 consecutive patients at time of diagnosis of malignant disease prior receiving anticancer therapy. Plasma GDF-15 concentrations were determined alongside other cardiac and routine laboratory markers. All-cause mortality was defined as primary endpoint. RESULTS: GDF-15 levels were 338 ng/L (IQR:205-534) for the total cohort, and values were comparable for different tumour entities except breast cancer. Metastatic disease was characterized by higher plasma GDF-15 [435 ng/L (IQR:279-614) vs 266 ng/L (IQR:175-427), P < .001]. GDF-15 correlated positively with inflammatory status reflected by CRP, SAA and IL-6 [r = .31, P < .001, r = .23, P < .001 and r = .14, P = .002] and cardiac biomarkers as NT-proBNP, hsTnT, MR-proADM and CT-proET-1 [r = .46; r = .46; r = .59 and r = .50; P < .001 for all]. GDF-15 was significantly associated with all-cause mortality after multivariate adjustment [adj.HR for ln(GDF-15) 1.78, 95%CI:1.47-2.16, P < .001]. There was a significant interaction between solid and haematological malignancies with loss of association of GDF-15 with outcome in myelodysplastic and myeloproliferative disease. CONCLUSIONS: Elevated plasma GDF-15 is associated with progressing disease severity and poor prognosis in solid tumours of treatment-naïve cancer patients. GDF-15 increase is accompanied by worsening systemic inflammation and a subclinical functional impairment of different organs including the heart. GDF-15 represents a promising target for our pathophysiologic understanding in cardio-oncology linking conditions of both cardiac and neoplastic disease.
No takes yet. Share an insight, caveat, or question.
Arfsten et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: